Modalis Therapeutics Corporation

TSE:4883 Stock Report

Market Cap: JP¥6.9b

Modalis Therapeutics Past Earnings Performance

Past criteria checks 0/6

Modalis Therapeutics's earnings have been declining at an average annual rate of -41.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 111.5% per year.

Key information

-41.3%

Earnings growth rate

-38.3%

EPS growth rate

Biotechs Industry Growth31.9%
Revenue growth rate-111.5%
Return on equity-74.4%
Net Marginn/a
Next Earnings Update13 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Modalis Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4883 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-1,8702401,583
30 Jun 240-2,1382321,912
31 Mar 240-2,3162452,081
31 Dec 230-2,3912482,102
30 Sep 230-2,9742331,972
30 Jun 230-2,9602211,989
31 Mar 230-2,7962191,862
31 Dec 2240-2,7022131,861
30 Sep 2240-1,8661991,806
30 Jun 2240-1,5301971,438
31 Mar 2241-1,3771921,267
31 Dec 211-7381961,009
30 Sep 213-415199676
30 Jun 216-457209676
31 Mar 21329-129195634
31 Dec 20342-448174531
31 Dec 19644140184303
31 Dec 1865-21762217

Quality Earnings: 4883 is currently unprofitable.

Growing Profit Margin: 4883 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4883 is unprofitable, and losses have increased over the past 5 years at a rate of 41.3% per year.

Accelerating Growth: Unable to compare 4883's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4883 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-36.8%).

Return on Equity

High ROE: 4883 has a negative Return on Equity (-74.44%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 13:18
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Modalis Therapeutics Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Akinori UedaGoldman Sachs
Kiyokazu YamazakiIchiyoshi Research Institute Inc.
Tomohiro TanakaSMBC NIKKO